Targeting Janus kinases in the treatment of autoimmune disease

Key Takeaways for GI Nurses

• Janus kinase (JAK) inhibitors are an increasingly important class of oral immunomodulatory medications used to treat inflammatory bowel disease (IBD), including ulcerative colitis, and GI nurses will encounter more patients on these agents in both infusion/injection clinics and endoscopy pre-procedure screening.
• Because JAK3 signaling is tied to multiple cytokine pathways (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21), patients on JAK inhibitors have altered immune function, which has direct implications for infection risk assessment, pre-procedure screening, and post-procedure monitoring in endoscopy units.
• Understanding the basic mechanism of JAK inhibition helps nurses better educate patients about why these medications are prescribed, what side effects to watch for (infections, cytopenias, thrombosis risk), and the rationale for lab monitoring before and after endoscopic procedures.
• This foundational research underlies an entire drug class relevant across GI, rheumatology, and dermatology—GI nurses should recognize these medications on medication reconciliation lists even when the primary indication isn't gastrointestinal (e.g., rheumatoid arthritis, psoriatic arthritis, atopic dermatitis).

Clinical Relevance

This research describes the discovery of Jak3, a critical enzyme in cytokine signaling, and the therapeutic strategy of targeting Janus kinases to modulate immune-mediated disease. While the original science is decades old, its clinical fruit is now squarely in GI nursing practice: JAK inhibitors such as tofacitinib and upadacitinib are approved and widely used for moderate-to-severe ulcerative colitis, and are under investigation for Crohn's disease. GI nurses working in infusion centers, IBD clinics, and endoscopy suites need a working understanding of how these drugs function—by blocking intracellular signaling downstream of cytokine receptors—to appropriately counsel patients and anticipate clinical issues.

From an operational standpoint, patients on JAK inhibitors require specific pre-procedure considerations. Because these medications broadly suppress cytokine-mediated immune responses, patients may be at increased risk for infection, and some guidelines recommend holding JAK inhibitors prior to major procedures or surgery. Endoscopy nurses performing pre-procedure assessments should be alert to current JAK inhibitor use, confirm whether gastroenterologists or rheumatologists have given hold instructions, and document baseline labs (CBC, lipid panel, liver function) that are routinely monitored in these patients. Nurses should also be prepared to discuss with patients the characteristic side-effect profile of this class—herpes zoster reactivation, venous thromboembolism risk, and cytopenias—since patients frequently ask about these risks during pre-procedure teaching or when colonoscopy is being considered for IBD surveillance or flare assessment.

On a professional development level, this research underscores the value of GI nurses staying current with the evolving pharmacology of IBD management, as treatment paradigms shift rapidly from biologics toward small-molecule oral therapies like JAK inhibitors. Nurses who understand the mechanistic basis for these drugs—rooted in fundamental cytokine biology—are better equipped to answer patient questions, participate in shared decision-making discussions, and serve as a knowledgeable bridge between the prescribing physician and the patient navigating a complex, lifelong treatment regimen.

Bottom Line

JAK inhibitors, a drug class built on foundational discoveries about Janus kinase signaling, are now mainstay therapies for ulcerative colitis and other autoimmune conditions seen in GI practice—GI nurses should know to screen for these medications during pre-procedure assessments, understand their infection and immune-suppression implications, and be ready to provide informed patient education around this rapidly growing treatment category.